Astellas Pharma (OTCMKTS:ALPMY) Sees Unusually-High Trading Volume – Time to Buy?

Shares of Astellas Pharma Inc. (OTCMKTS:ALPMY) saw strong trading volume on Tuesday . 317,850 shares traded hands during mid-day trading, an increase of 212% from the previous session’s volume of 101,867 shares.The stock last traded at $14.42 and had previously closed at $14.38.

Analyst Ratings Changes

ALPMY has been the subject of several recent research reports. Citigroup lowered shares of Astellas Pharma from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 19th. Zacks Research lowered shares of Astellas Pharma from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 22nd. Three equities research analysts have rated the stock with a Hold rating, According to MarketBeat.com, Astellas Pharma presently has an average rating of “Hold”.

Astellas Pharma Stock Up 0.1%

The firm’s 50-day simple moving average is $13.48 and its 200 day simple moving average is $11.83. The company has a quick ratio of 0.80, a current ratio of 1.03 and a debt-to-equity ratio of 0.20.

Astellas Pharma (OTCMKTS:ALPMY) last issued its quarterly earnings results on Thursday, October 30th. The company reported $0.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.20 by $0.10. The company had revenue of $3.45 billion for the quarter, compared to analysts’ expectations of $3.14 billion. Astellas Pharma had a return on equity of 22.21% and a net margin of 6.39%. As a group, equities analysts expect that Astellas Pharma Inc. will post 0.42 earnings per share for the current year.

About Astellas Pharma

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).